Skip to main content
OpenTrials
Completed

NCT Number: NCT05078229

Evaluating Stress Management Among Allogeneic HCT Caregivers

The purpose of the study is to understand whether different stress management interventions impact stress among HCT cancer caregivers and patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Burden Stress

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Moffitt Cancer Center

Tampa, Florida, 33612, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Caregiver Inclusion Criteria:
  • Caring for a patient planning to receive an allogeneic HCT at Moffitt
  • Intending to remain primary caregiver throughout patient treatment (i.e., will be the caregiver the majority of the time)
  • Able to provide informed consent
  • Able to read and write in English
  • Owns a smartphone and is willing to download the study app
  • Patient Inclusion Criteria:
  • Receiving an allogeneic HCT at the cancer center
  • Able to provide informed consent
  • Able to read and write in English

Exclusion criteria

  • Under 21 years of age
  • Unable to provide informed consent
  • Unable to read and write in English
  • Caregiver is unable to remain primary caregiver throughout patient treatment
  • Patient does not receive transplant at Moffitt Cancer Center

Treatment and study plan

Focus

Behavioral

There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of the sessions will be Mindfulness for the Caregivers, Awareness of Stressors, Skillful Actions, Thoughts, Self-Care and Balance and Planning for the Future. There will be meditation during the sessions and then recommended daily at home mindfulness practice.

Healthy Living

Behavioral

There will be 6 one on one sessions, either in person or via video conference. The 6 sessions will last between 45-60 minutes. Topics of sessions will be Overview of Cancer, Eating Well, Exercise, Cancer Prevention, Sleep and Finances.

Primary outcomes

  1. Caregiver Burden at End of Treatment

    Time frame: Up to 8 Weeks

    Caregiver burden will be measured using the Zarit Burden Interview Short Form (ZBI). The ZBI is 12 items using a 5-point Likert scale assessing caregiver burden. Participants rate burden on a scale of 0 to 4, 0 indicating "rarely" an issue and 4 indicating "nearly always" The ZBI has been validated in populations of cancer caregivers and has demonstrated very good internal consistency and discriminative ability

  2. Caregiver Burden at 2 Month Follow-up

    Time frame: 2 month follow up after end of treatment

    Caregiver burden will be measured using the Zarit Burden Interview Short Form (ZBI). The ZBI is 12 items using a 5-point Likert scale assessing caregiver burden. Participants rate burden on a scale of 0 to 4, 0 indicating "rarely" an issue and 4 indicating "nearly always". The ZBI has been validated in populations of cancer caregivers and has demonstrated very good internal consistency and discriminative ability

  3. Caregiver Burden at 6 Month Follow-up

    Time frame: 6 month follow up after end of treatment

    Caregiver burden will be measured using the Zarit Burden Interview Short Form (ZBI). The ZBI is 12 items using a 5-point Likert scale assessing caregiver burden. Participants rate burden on a scale of 0 to 4, 0 indicating "rarely" an issue and 4 indicating "nearly always". The ZBI has been validated in populations of cancer caregivers and has demonstrated very good internal consistency and discriminative ability

  4. Patient Distress at End of Treatment (CESD)

    Time frame: Up to 8 Weeks

    Patient distress will be measured using the Center for Epidemiological Studies Depression Scale (CESD). The CESD is comprised of 20 4-point Likert scale items and has been commonly used among cancer caregivers. Participants rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms.

  5. Patient Distress at End of Treatment (GAD-7)

    Time frame: Up to 8 Weeks

    Patient distress will be measured using the Generalized Anxiety Disorder-7 (GAD-7). The GAD-7 is comprised of 8 items on a 4-point Likert scale and has been used extensively among cancer caregivers. Participants rate the severity of his or her symptoms over the past two weeks. The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of "not at all," "several days," "more than half the days," and "nearly every day," respectively, and then adding together the scores for the seven questions

  6. Patient Distress at 2 Month Follow-up (CESD)

    Time frame: 2 Month Follow-up after end of treatment

    Patient distress will be measured using the Center for Epidemiological Studies Depression Scale (CESD). The CESD is comprised of 20 4-point Likert scale items and has been commonly used among cancer caregivers. Participants rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms.

  7. Patient Distress at 2 Month Follow-up (GAD-7)

    Time frame: 2 Month Follow-up after end of treatment

    Patient distress will be measured using the Generalized Anxiety Disorder-7 (GAD-7). The GAD-7 is comprised of 8 items on a 4-point Likert scale and has been used extensively among cancer caregivers. Participants rate the severity of his or her symptoms over the past two weeks. The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of "not at all," "several days," "more than half the days," and "nearly every day," respectively, and then adding together the scores for the seven questions

  8. Patient Distress at 6 Month Follow-up (CESD)

    Time frame: 6 Month Follow-up after end of treatment

    Patient distress will be measured using the Center for Epidemiological Studies Depression Scale (CESD). The CESD is comprised of 20 4-point Likert scale items and has been commonly used among cancer caregivers. Participants rate how often over the past week they experienced symptoms associated with depression, such as restless sleep, poor appetite, and feeling lonely. Response options range from 0 to 3 for each item (0 = Rarely or None of the Time, 1 = Some or Little of the Time, 2 = Moderately or Much of the time, 3 = Most or Almost All the Time). Scores range from 0 to 60, with high scores indicating greater depressive symptoms.

  9. Patient Distress at 6 Month Follow-up (GAD-7)

    Time frame: 6 Month Follow-up after end of treatment

    Patient distress will be measured using the Generalized Anxiety Disorder-7 (GAD-7). The GAD-7 is comprised of 8 items on a 4-point Likert scale and has been used extensively among cancer caregivers. Participants rate the severity of his or her symptoms over the past two weeks. The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of "not at all," "several days," "more than half the days," and "nearly every day," respectively, and then adding together the scores for the seven questions

Secondary outcomes

  1. Patient Healthcare Utilization - Readmissions to the hospital at 6 Month Follow-up

    Time frame: 6 Month Follow-up after end of treatment

    Patient Healthcare Utilization will be measured with readmissions to the hospital

  2. Patient Healthcare Utilization - unexpected clinic visits post discharge at 6 Month Follow-up

    Time frame: 6 Month Follow-up after end of treatment

    Patient Healthcare Utilization will be measured with unexpected clinic visits post discharge

Sponsors and collaborators

Lead sponsor

H. Lee Moffitt Cancer Center and Research Institute

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Efficacy of a Mindfulness-Based Stress Management Program for Allogeneic HCT Caregivers

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Oct 14, 2021
Registry last updated
Jul 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.